Startup profile · funding coverage
EQRx
EQRx launched in 2020 to develop lower-cost branded medicines but wound down programs after a 2023 acquisition by Revolution Medicines.
Stage
acquired
Status
acquired
Coverage
full
Why EQRx is interesting
Alexis Borisy’s “fast follower” pricing thesis raised $2B+ in venture and SPAC capital before FDA setbacks forced a strategic reset — a cautionary tale in biotech capital efficiency.
Key facts
- Series A (Jan 2020): $200M co-led by ARCH Venture Partners, GV, and a16z (Businesswire)
- Exit (Nov 2023): Acquired by Revolution Medicines; EQRx wound down R&D programs (BioPharma Dive)
Investors in our directory
Funds linked from EQRx's profile — open a fund page for stage focus and related deal articles.
Industries
Generalist Technology
Industry hub pages are rolling out from our fund-derived baseline taxonomy.
Related funding articles
Venture Capital Tracker pieces that cover EQRx's financing or category context.
Last updated: 2026-07-24